Reaction Details |
| Report a problem with these data |
Target | Serine/threonine-protein kinase receptor R3 |
---|
Ligand | BDBM50262685 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_961935 (CHEMBL2390526) |
---|
IC50 | 106±n/a nM |
---|
Citation | Engers, DW; Frist, AY; Lindsley, CW; Hong, CC; Hopkins, CR Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett23:3248-52 (2013) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Serine/threonine-protein kinase receptor R3 |
---|
Name: | Serine/threonine-protein kinase receptor R3 |
Synonyms: | ACVL1_HUMAN | ACVRL1 | ACVRLK1 | ALK1 | Activin receptor-like kinase 1 (ALK-1) | Serine/threonine-protein kinase receptor R3 (ALK1) |
Type: | Enzyme |
Mol. Mass.: | 56134.46 |
Organism: | Homo sapiens (Human) |
Description: | P37023 |
Residue: | 503 |
Sequence: | MTLGSPRKGLLMLLMALVTQGDPVKPSRGPLVTCTCESPHCKGPTCRGAWCTVVLVREEG
RHPQEHRGCGNLHRELCRGRPTEFVNHYCCDSHLCNHNVSLVLEATQPPSEQPGTDGQLA
LILGPVLALLALVALGVLGLWHVRRRQEKQRGLHSELGESSLILKASEQGDSMLGDLLDS
DCTTGSGSGLPFLVQRTVARQVALVECVGKGRYGEVWRGLWHGESVAVKIFSSRDEQSWF
RETEIYNTVLLRHDNILGFIASDMTSRNSSTQLWLITHYHEHGSLYDFLQRQTLEPHLAL
RLAVSAACGLAHLHVEIFGTQGKPAIAHRDFKSRNVLVKSNLQCCIADLGLAVMHSQGSD
YLDIGNNPRVGTKRYMAPEVLDEQIRTDCFESYKWTDIWAFGLVLWEIARRTIVNGIVED
YRPPFYDVVPNDPSFEDMKKVVCVDQQTPTIPNRLAADPVLSGLAQMMRECWYPNPSARL
TALRIKKTLQKISNSPEKPKVIQ
|
|
|
BDBM50262685 |
---|
n/a |
---|
Name | BDBM50262685 |
Synonyms: | 6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine | 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine | CHEMBL478629 | Dorsomorphin | US9040694, Dorsomorphin |
Type | Small organic molecule |
Emp. Form. | C24H25N5O |
Mol. Mass. | 399.4882 |
SMILES | C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1 |
Structure |
|